top of page
Search

PATENT US6514984B1 04.02.2003 DRUG FOR DEMENTIA AND ALZHEIMER'S

According to the WHO, 55 million people worldwide suffered in 2022 from dementia, number which increases every year with about 10 million.

In August 2018, the Dementia Expertise Centre Flanders and the Alzheimer's League Flanders jointly published new figures on the evolution of the number of people with dementia per municipality from 2018 to 2035.

For the entire Flemish Region, the number of people with dementia in 2018 was estimated at 131,818. Both bodies predicted that this figure would rise to 188,183 by 2035, or + a 42.7% increase. That's an awful lot.


It is reported that 60-70% of all dementia is due to Alzheimer's disease. Today, there is officially no effective treatment against this condition. People gradually degenerate and die over time without any consciousness.

However, since December 2000, there is a drug that can prevent and treat or at least significantly slow down the condition.

Indeed, in December 2020, August Masaru Watanabe filed a patent application with the US Patent Office for a method of preventing and treating Alzheimer's disease by administering an effective amount of a substituted tricyclic sPLA2 inhibitor.

This patent was allowed on 04 February 2003 after the usual worldwide examination and registered under patent number US6514984B1.


The drug has never marketed. Why not? Any pharmaceutical giant could have appropriated the method and commercialised the drug. The patent expired the following year for non-payment of the fee and has been freely available ever since ( note : those who want the protection of their invention through a patent have to pay a high annual fee per country for which they want that protection ).

It is very strange that no drug is being developed against dementia and Alzheimer's, especially now that the condition is on the rise and millions of sufferers are added every year.


Dementia is the loss of cognitive functioning - thinking, remembering and reasoning - and behavioural skills to the extent that it interferes with a person's daily life and activities. Dementia ranges in severity from the mildest stage, when a person's functioning is impaired, to the most severe stage, when the person is completely dependent on others for help with basic activities of daily living.

Alzheimer's disease is a brain disorder that slowly destroys memory and thinking skills, and eventually the ability to perform the simplest tasks. In most people with Alzheimer's, symptoms do not appear until later in life, but younger people can also contract the condition.

Alzheimer's disease is named after Dr Alois Alzheimer. In 1906, Dr Alzheimer noticed changes in the brain tissue of a woman who had died of an unusual mental illness. Her symptoms were memory loss, language problems and unpredictable behaviour. After her death, he examined her brain and found many abnormal clumps ( now called plaques ) and bundles of fibres (now called neurofibrillary tangles). Another feature is the loss of connections between neurons in the brain. Neurons send messages between different parts of the brain and from the brain to muscles and organs in the body.

In the early 20th century, the disease was rare. As as the 20th century went on, more and more people were caught with the disease, scientists investigated the possible causes. In 2003, a highly comprehensive European study showed a direct link between the presence of aluminium nanoparticles in the brain and the development of Alzheimer's disease. Numerous human rights organisations seized on this study to initiate legal proceedings against vaccine manufacturers. These aluminium nano particles reportedly not only cause Alzheimer's in the elderly but also ADHD, autism and paralysis in children.







13 views0 comments

תגובות


bottom of page